Home › Small Cell Lung Cancer › Oklahoma › Oklahoma City
Small Cell Lung Cancer clinical trials in Oklahoma City, OK
4 studies for Small Cell Lung Cancer are looking for participants at sites in and around Oklahoma City (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
RecruitingPhase 1/2
- University of Oklahoma, Oklahoma City
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
RecruitingPhase 1
- OU Health University of Oklahoma Medical Center, Oklahoma City
- Stephenson Cancer Center (chemo location), Oklahoma City
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
RecruitingPhase 1/2
- Sarah Cannon Research Institute University of Oklahoma, Oklahoma City
Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study
RecruitingPhase 2
- University of Oklahoma Health Sciences Center, Oklahoma City
Small Cell Lung Cancer trials in other cities
- Houston, TX26 studies
- Arlington, VA23 studies
- New York City, NY22 studies
- Boston, MA21 studies
- Nashville, TN20 studies
- Los Angeles, CA20 studies
- Orlando, FL15 studies
- Dallas, TX13 studies
- Cleveland, OH13 studies
- Chicago, IL13 studies
- St. Louis, MO13 studies
- Detroit, MI12 studies
Other studies in Oklahoma City
- Non-Small Cell Lung Cancer28 studies
- Ovarian Cancer28 studies
- Endometrial Cancer25 studies
- Colorectal Cancer22 studies
- Prostate Cancer21 studies
- Lung Cancer19 studies
- Breast Cancer17 studies
- Metastatic Cancer16 studies
- Cancer (all types)14 studies
- Acute Myeloid Leukemia14 studies
- Head and Neck Squamous Cell Carcinoma13 studies
- Bladder Cancer11 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.